Join Growin Stock Community!
Beta
Back to RXRX.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
operating-expenses-chart

RXRX Operating Expenses

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

In Q1'26, RXRX's total operating expenses reached $122.5M USD, comprising $88M USD in R&D expenses and $34.6M USD in SG&A expenses, reflecting a decline from the prior quarter's peak. From Q2'23 to Q1'26, R&D expenses exhibited strong growth, surging from $55.1M USD to a high of $129.6M USD in Q1'25 before tapering to $88M USD, indicating a shift from aggressive investment to moderation. SG&A expenses showed steady increases to $77.2M USD in Q4'24, followed by a consistent downward trend to $34.6M USD, resulting in overall operating expenses that escalated rapidly through 2024 before stabilizing and declining in 2025-26, suggesting improved cost control amid evolving business priorities.